Thilo Mohns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thilo Mohns has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Andre A Kroon
Department of Paediatrics, Division of Neonatology, Erasmus Medical Centre Rotterdam, Sophia Children’s Hospital, ‘s Gravendijkwal 230, 3015, CE, Rotterdam, The Netherlands
1 shared publication - Anne Debeer
Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium
1 shared publication - Anne P. De Jaegere
Department of Neonatology, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands
1 shared publication - Anton Hubertus van Kaam
Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, Amsterdam, Netherlands
1 shared publication - Arjan B. Te Pas
Leiden University Medical Center
1 shared publication - Arno F. J. van Heijst
Department of Neonatology, Radboud university medical center, Nijmegen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 4 January 2012
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 6 (1) , 1
Paracetamol serum concentrations in preterm infants treated with paracetamol intravenously: a case series
Until now, studies on paracetamol given intravenously have mainly been performed with the pro-drug propacetamol or with paracetamol in preterm babies above 32 weeks of gestation. Studies in these babies indicate that intravenous paracetamol is tolerated well, however studies on the efficacy of intravenous paracetamol are lacking. There are no pharmacokinetic data on the administration of multiple doses of paracetamol in preterm babies with a gestational age below 32 weeks.
- 4 January 2012
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 6 (1) , 1
Open AccessParacetamol serum concentrations in preterm infants treated with paracetamol intravenously: a case series
Until now, studies on paracetamol given intravenously have mainly been performed with the pro-drug propacetamol or with paracetamol in preterm babies above 32 weeks of gestation. Studies in these babies indicate that intravenous paracetamol is tolerated well, however studies on the efficacy of intravenous paracetamol are lacking. There are no pharmacokinetic data on the administration of multiple doses of paracetamol in preterm babies with a gestational age below 32 weeks.
- Open Access
- 9 November 2011
- Published by Springer Nature in BMC Pediatrics
- Vol. 11 (1) , 102
Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial
Background: Randomized controlled trials have shown that treatment of chronically ventilated preterm infants after the first week of life with dexamethasone reduces the incidence of the combined outcome death or bronchopulmonary dysplasia (BPD). However, there are concerns that dexamethasone may increase the risk of adverse neurodevelopmental outcome. Hydrocortisone has been suggested as an alternative therapy. So far no randomized controlled trial has investigated its efficacy when administered after the first week of life to ventilated preterm infants. Methods/Design: The SToP-BPD trial is a randomized double blind placebo controlled multicenter study including 400 very low birth weight infants (gestational age < 30 weeks and/or birth weight < 1250 grams), who are ventilator dependent at a postnatal age of 7 - 14 days. Hydrocortisone (cumulative dose 72.5 mg/kg) or placebo is administered during a 22 day tapering schedule. Primary outcome measure is the combined outcome mortality or BPD at 36 weeks postmenstrual age. Secondary outcomes are short term effects on the pulmonary condition, adverse effects during hospitalization, and long-term neurodevelopmental sequelae assessed at 2 years corrected gestational age. Analysis will be on an intention to treat basis. Discussion: This trial will determine the efficacy and safety of postnatal hydrocortisone administration at a moderately early postnatal onset compared to placebo for the reduction of the combined outcome mortality and BPD at 36 weeks postmenstrual age in ventilator dependent preterm infants. Trial registration number: Netherlands Trial Register (NTR): NTR2768
- 9 November 2011
- Published by Springer Nature in BMC Pediatrics
- Vol. 11 (1) , 102
Open AccessSystemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial
Background: Randomized controlled trials have shown that treatment of chronically ventilated preterm infants after the first week of life with dexamethasone reduces the incidence of the combined outcome death or bronchopulmonary dysplasia (BPD). However, there are concerns that dexamethasone may increase the risk of adverse neurodevelopmental outcome. Hydrocortisone has been suggested as an alternative therapy. So far no randomized controlled trial has investigated its efficacy when administered after the first week of life to ventilated preterm infants. Methods/Design: The SToP-BPD trial is a randomized double blind placebo controlled multicenter study including 400 very low birth weight infants (gestational age < 30 weeks and/or birth weight < 1250 grams), who are ventilator dependent at a postnatal age of 7 - 14 days. Hydrocortisone (cumulative dose 72.5 mg/kg) or placebo is administered during a 22 day tapering schedule. Primary outcome measure is the combined outcome mortality or BPD at 36 weeks postmenstrual age. Secondary outcomes are short term effects on the pulmonary condition, adverse effects during hospitalization, and long-term neurodevelopmental sequelae assessed at 2 years corrected gestational age. Analysis will be on an intention to treat basis. Discussion: This trial will determine the efficacy and safety of postnatal hydrocortisone administration at a moderately early postnatal onset compared to placebo for the reduction of the combined outcome mortality and BPD at 36 weeks postmenstrual age in ventilator dependent preterm infants. Trial registration number: Netherlands Trial Register (NTR): NTR2768